Werewolf Therapeutics Q2 2026: Going Concern Doubt, Nasdaq Delisting Risk, and Dwindling Cash
HOWL sits 81% above its 52-week low of $0.27.
Summary
Werewolf Therapeutics' Q2 2026 report reveals a going concern warning, a cash balance of just $22 million, and Nasdaq delisting risk. The company has cut over 80% of its workforce and is pursuing a strategic review.
Key Events · Earnings and Guidance · HOWL
-
Going Concern Warning
Management states there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the issuance date of these financial statements.
-
Cash Burn and Liquidity
Cash and cash equivalents fell to $22.0 million as of June 30, 2026, from $57.1 million at year-end 2025. Operating activities consumed $4.0 million during the first half of 2026.
-
Nasdaq Delisting Risk
The stock price has been below $1.00 since February 2026. With the compliance deadline of August 3, 2026, approaching and no recovery yet, delisting would severely impair liquidity and the ability to raise capital.
-
Workforce Reductions
A 64% workforce reduction occurred in February 2026, followed by an additional 36% reduction in May 2026, leaving a skeleton crew to manage the strategic review.
Analysis · HOWL · Life Sciences
The 10-Q from Werewolf Therapeutics paints a dire financial picture. With cash reserves down to $22 million, management explicitly warns of substantial doubt about the company's ability to continue as a going concern. The stock, trading at $0.49, sits far below the $1.00 Nasdaq minimum, and the August 3, 2026 compliance deadline looms without a recovery in sight. Already, the workforce has been slashed by over 80% cumulatively, the key asset was sold to Jazz for $21 million, and debt has been repaid. Lacking approved products and deep in a strategic review, the company's options are rapidly narrowing. This filing confirms the market's worst fears about its viability.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.